Promising new combo therapy for advanced lung cancer enters phase 2 trial
NCT ID NCT07103395
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with a type of advanced lung cancer that cannot be removed by surgery. It tests a new approach that combines chemotherapy, radiation, and two types of immunotherapy to see if it can control the cancer longer. The trial involves 56 participants and aims to measure how well the treatment works and what side effects occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
- New radiation technique aims to shield airways and preserve lung function
- AI assistant could help junior doctors plan lung cancer surgeries
- New drug cocktail targets Hard-to-Treat lung cancer
- App-Based breathing training aims to boost lung cancer recovery